Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2022
Reporting Period: First fiscal quarter ended December 31, 2021
This filing announces the release of financial results for the first fiscal quarter of 2022. The report includes a press release (Exhibit 99.1) containing both GAAP and non-GAAP financial measures.
Key Financial Metrics
The filing text serves as a notification of the results release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1).
Non-GAAP Measures Discussed:
- Currency-Neutral Revenue Growth: Revenue growth rates adjusted to eliminate the effect of foreign currency translation.
- Adjusted Diluted Earnings Per Share (EPS): EPS adjusted to exclude items not considered part of ordinary operations, including:
- Purchase accounting adjustments
- Integration and restructuring costs
- Spin-off related charges
- Transaction gains and losses
- Legal defense and product remediation costs
- Regulatory costs
- Investment gains and losses
- Impact of debt extinguishment
- Dilutive impact of outstanding preferred stock
Material Changes and Comparisons
The filing text does not provide specific data on material changes versus the prior comparable period. It states that management presents currency-neutral and adjusted metrics to facilitate period-to-period comparisons and to help investors understand underlying operating trends.
Guidance, Outlook, and Management Commentary
Outlook: Management presents estimated revenue and adjusted EPS growth for the full fiscal year 2022, adjusted for the anticipated impact of foreign currency translation.
Management Commentary:
- Management utilizes non-GAAP measures to evaluate underlying performance, analyze base operating results, and forecast future prospects.
- These measures are intended to improve transparency regarding operational decision-making and allow for comparison with other medical technology companies.
- Cautionary Note: Management emphasizes that non-GAAP measures are not replacements for GAAP results. Items excluded from non-GAAP measures may have a material impact on net income, EPS, or cash flows. Investors are encouraged to review consolidated financial statements in their entirety.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific GAAP and non-GAAP financial figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the magnitude of excluded items (e.g., restructuring, legal costs).
- Assess the impact of foreign currency translation on reported revenue growth versus currency-neutral growth.
- Examine the specific components of the "Adjusted EPS" to evaluate the sustainability of earnings.
- Review the full fiscal year 2022 guidance provided in the press release for revenue and adjusted EPS growth estimates.